CN116870104A - Application of bamboo liquid particle compound in medicines or daily chemicals for treating dermatitis - Google Patents
Application of bamboo liquid particle compound in medicines or daily chemicals for treating dermatitis Download PDFInfo
- Publication number
- CN116870104A CN116870104A CN202310985360.0A CN202310985360A CN116870104A CN 116870104 A CN116870104 A CN 116870104A CN 202310985360 A CN202310985360 A CN 202310985360A CN 116870104 A CN116870104 A CN 116870104A
- Authority
- CN
- China
- Prior art keywords
- bamboo
- bamboo liquid
- liquid particle
- dermatitis
- treating dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000017166 Bambusa arundinacea Nutrition 0.000 title claims abstract description 102
- 235000017491 Bambusa tulda Nutrition 0.000 title claims abstract description 102
- 241001330002 Bambuseae Species 0.000 title claims abstract description 102
- 235000015334 Phyllostachys viridis Nutrition 0.000 title claims abstract description 102
- 239000011425 bamboo Substances 0.000 title claims abstract description 102
- 239000007788 liquid Substances 0.000 title claims abstract description 89
- 239000002245 particle Substances 0.000 title claims abstract description 61
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 56
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 150000001875 compounds Chemical class 0.000 title claims abstract description 29
- 239000000126 substance Substances 0.000 title claims abstract description 27
- 229940079593 drug Drugs 0.000 title claims abstract description 22
- 239000002131 composite material Substances 0.000 claims description 11
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims description 11
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 10
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 10
- 229910052586 apatite Inorganic materials 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 210000001821 langerhans cell Anatomy 0.000 claims description 5
- 210000002540 macrophage Anatomy 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000006260 foam Substances 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 230000002500 effect on skin Effects 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 5
- 239000006210 lotion Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 208000010668 atopic eczema Diseases 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 235000021419 vinegar Nutrition 0.000 description 6
- 239000000052 vinegar Substances 0.000 description 6
- 206010012434 Dermatitis allergic Diseases 0.000 description 5
- 201000008937 atopic dermatitis Diseases 0.000 description 5
- 231100000314 skin damage score Toxicity 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010016936 Folliculitis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000013115 immunohistochemical detection Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 231100000245 skin permeability Toxicity 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010045210 Tympanic Membrane Perforation Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 125000002345 steroid group Chemical group 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The application relates to an application of a bamboo liquid particle compound in a medicine or daily chemical product for treating dermatitis. The bamboo liquid particle compound has obvious anti-skin inflammation effect, and the bamboo liquid particle compound is applied to medicines or daily chemicals for treating the skin inflammation, and can be milder and safer while effectively treating the skin inflammation due to the purely natural property of the bamboo liquid.
Description
Technical Field
The application relates to the field of biotechnology, in particular to application of a bamboo liquid particle compound in medicines or daily chemicals for treating dermatitis.
Background
Allergic dermatitis such as eczema causes skin surface cells to easily fall off, the skin loses due natural protection function, and the resistance of the skin is reduced. The chemicals, allergens, penetrate the skin of a patient and stimulate immune cells of the skin for a long time, thereby forming skin allergy phenomena. The inflamed parts of allergic dermatitis patients have the phenomenon of redness and swelling, and the appearance is affected. If the red and swelling phenomenon is continuous, the normal life and sleep quality of the patient are affected. Worldwide, 10% of adults and 15% of children suffer from eczema.
Methods for treating allergic dermatitis include protecting the skin, preventing contact with allergens or stimulating the skin, and using anti-inflammatory drugs. The external medicine is widely used in dermatology, and the most common medicine is steroid (hormone) eczematous dermatitis medicine. Steroid eczematous dermatitis drugs are first-line therapeutic drugs for allergic and immunological disorders of skin, but the use of excessive steroid may cause folliculitis and other adverse reactions.
In recent years, research into natural plants by the scientific community and consumer interest in natural plants have grown. From the prior art, the individual bamboo liquid is coated on the dermatitis part, and compared with the blank control group which is not treated, the bamboo liquid has the anti-dermatitis effect, but the anti-dermatitis effect of the bamboo liquid is not widely used so far. The reasons are as follows: 1. the lack of scientific experiments proves that the lack of mechanism verification; 2. the skin permeability of the active ingredient is low; 3. the peculiar smell of the bamboo liquid is not accepted by users.
Disclosure of Invention
Aiming at the defects that the existing medicines for treating dermatitis are first-line medicines for treating allergic and immune disorder skin diseases, but excessive steroid is likely to cause folliculitis and other adverse reactions, and single bamboo liquid has anti-dermatitis effect, but is not widely used so far, the application provides the application of the bamboo liquid particle compound in medicines or daily chemicals for treating dermatitis.
The above object of the present application is achieved by the following technical solutions:
in the existing medicines for treating dermatitis, steroid eczematous dermatitis is a first-line treatment medicine for allergic and immune disorder dermatosis, but excessive steroid is likely to cause folliculitis and other adverse reactions, and independent bamboo liquid has anti-dermatitis effect, but the medicine has not been widely used so far.
The application provides an application of a bamboo liquid particle compound in medicines or daily chemicals for treating dermatitis. Due to the pure natural property of the bamboo liquid, the bamboo liquid can be milder and safer while effectively treating dermatitis.
Preferably, the bamboo liquid particle composite is a particle composite formed by bamboo liquid and apatite carbonate particles.
Further preferably, the bamboo liquid particle complex is applied to a medicine or a daily chemical product for treating dermatitis in a liquid or solid form.
Further preferably, the bamboo liquid particle complex is applied to a drug or daily chemical product for treating dermatitis in the form of a solution or suspension.
Preferably, the drug or daily chemical product for treating dermatitis containing the bamboo liquid particle complex is liquid or solid.
Further preferably, the drug or daily chemical product for treating dermatitis containing the bamboo liquid particle composite is any one of a coating liquid preparation, a spray preparation, a suspension, a paste preparation and a foam preparation.
Preferably, the bamboo fluid particle complex promotes secretion of dermal langerhans cells and/or macrophages FGF-2.
The beneficial technical effects of the application are as follows:
the bamboo liquid particle compound has obvious anti-skin inflammation effect, and the bamboo liquid particle compound is applied to medicines or daily chemicals for treating the skin inflammation, and can be milder and safer while effectively treating the skin inflammation due to the purely natural property of the bamboo liquid.
Drawings
FIG. 1 is a schematic diagram showing the modeling of allergic dermatitis in the experimental example of the present application;
FIG. 2 is a graph showing cure of the back dermatitis of the mice in the experimental example of the present application;
FIG. 3 is a chart showing statistics of the skin damage scores of Day0 and Day4 in the experimental example of the present application;
FIG. 4 is a graph showing the statistics of the fold lines of the change in the skin inflammatory skin damage score of the mice according to the experimental example of the present application;
FIG. 5 is a graph of analysis of the che staining of the dermatitis pathology of the mice according to the experimental example of the present application;
FIG. 6 is a diagram showing the immunohistochemical expression of FGF-2 in the experimental example of the present application;
FIG. 7 is a diagram (I) showing a case of using the bamboo liquid particle composite of the present application;
FIG. 8 is a diagram of a case of using the bamboo liquid particle composite of the present application (II).
Detailed Description
The technical solutions in the embodiments of the present application will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present application; it is apparent that the described embodiments are only some embodiments of the present application, not all embodiments, and that all other embodiments obtained by persons of ordinary skill in the art without making creative efforts based on the embodiments in the present application are within the protection scope of the present application.
Examples
The application provides an application of a bamboo liquid particle compound in medicines or daily chemicals for treating dermatitis.
Preferably, the bamboo liquid particle composite is a particle composite formed by bamboo liquid and apatite carbonate particles.
Further preferably, the bamboo liquid particle complex is applied to a medicine or a daily chemical product for treating dermatitis in a liquid or solid form.
Further preferably, the bamboo liquid particle complex is applied to a drug or daily chemical product for treating dermatitis in the form of a solution or suspension.
Preferably, the drug or daily chemical product for treating dermatitis containing the bamboo liquid particle complex is liquid or solid.
Further preferably, the drug or daily chemical product for treating dermatitis containing the bamboo liquid particle composite is any one of a coating liquid preparation, a spray preparation, a suspension, a paste preparation and a foam preparation.
Wherein the bamboo liquid particle complex promotes secretion of FGF-2 by dermis Langerhans cells and/or macrophages
Application examples
The application of the bamboo liquid particle compound in medicines or daily chemicals for treating dermatitis, wherein the bamboo liquid particle compound comprises bamboo liquid and carbonic apatite particles, the bamboo liquid and the carbonic apatite particles form a particle compound, and the relative content of the bamboo liquid and the carbonic apatite particles is 3.25% and 96.75% in percentage by mass.
The method for preparing the bamboo liquid particle compound comprises the following steps:
s1, preparing 100mL of aqueous solution containing a mixture of bamboo liquid and inorganic ions, wherein the content of the bamboo liquid is 5% by mass, and 440mM NaHCO is added 3 9mM NaH 2 PO 4 58mM CaCl 2 ；
S2, stirring for 3 minutes at 20 ℃, and centrifuging at 4000rpm for 3 minutes to obtain a precipitate, namely the bamboo liquid particle compound.
Wherein the bamboo liquid can be selected from one or more of bamboo charcoal ash extract, bamboo ethanol soaking solution, bamboo vinegar solution, and bamboo leaf decoction.
As some of these embodiments, the bamboo juice manufacturing method optionally includes one of:
1. pulverizing bamboo, drying as required, and subjecting bamboo to dry distillation under reduced pressure condition, collecting distillate, wherein the reduced pressure condition is below 100mmHg, preferably 10-60 mmHg; more preferably 15 to 45 mmHg; the distillation temperature of the retort product depends on the degree of reduced pressure, and is high and low when the degree of reduced pressure is large, and is high when the degree of reduced pressure is small, for example, 180 to 200 ℃ when the pressure is reduced by 20 mmHg.
2. The crushed bamboo was fed to a vacuum distillation apparatus, vacuum distilled at a temperature of about 200℃and a pressure of about 20mmHg, and the distillate was diluted with ethanol.
3. The simple refining of crude bamboo vinegar mainly adopts natural standing method, the crude bamboo vinegar is placed in a container for standing for a period of time to naturally delaminate, the upper layer is light-colored clarified bamboo vinegar, and the lower layer is dark brown bamboo tar. Or mixing organic solvents such as benzene and chloroalum with bamboo vinegar solution according to different ratios, stirring, standing, separating into two layers, taking out the solution, distilling, taking out the solvent, and recovering. Other simple refining methods such as adsorption refining of charcoal, activated carbon and other articles are also adopted at present, and charcoal, bamboo charcoal, activated carbon and the like are mixed with crude bamboo vinegar according to a certain proportion, stirred, stood and filtered.
The application provides an application of the bamboo liquid particle compound prepared by the method in medicines or daily chemicals for treating dermatitis.
The medicine or daily chemical product for treating dermatitis exists in the forms of a coating liquid preparation, a spray preparation, a suspension, a paste preparation and a foam preparation, and the bamboo liquid particle compound can be added into the medicine or daily chemical product for treating dermatitis, so that the dermatitis can be effectively treated.
Experimental example
1. Introduction to allergic dermatitis modeling
As shown in FIG. 1, the mice were dehaired to remove back hair and were molded using DNCB, 2, 4-dinitrochlorobenzene. The first sensitization was performed on day 1 with 2% DNCB solution administered at 150uL back and 10uL post-aural, and the challenge was performed on days 5, 7, 9, 11, 13, 16, 18, 20, 22, 24 with 0.5% DNCB solution administered at 150uL back and 10uL post-aural. On day 25, the total score of the modeling condition is greater than or equal to 5 minutes through pathological section experiments, skin damage score and scratching experiments, and the model is successfully modeled.
Pathological section shows that the skin tissue structure of the control group is normal and no obvious pathological change is observed under an optical microscope; the stratum corneum of the skin tissue of the model group is keratinized, the epidermis layer is obviously thickened, and inflammatory cells in the dermis layer infiltrate.
2. Research and experiment of bamboo liquid particle compound on treatment effect of mice DNCB on induced dermatitis
Experimental mice: c57BL/6 mice male 6 weeks old;
experimental environment: the temperature is 20-26 ℃ and the humidity is 40-70%;
experimental grouping: the experiment was divided into 5 groups of 4;
1) Model set (do nothing);
2) 5% of bamboo liquid (spraying under 2/day), wherein the bamboo liquid comprises the water solution of the bamboo liquid, and the bamboo liquid content is calculated by mass percent, namely the bamboo liquid with the same concentration used in the step S1 of preparing the bamboo liquid particle compound;
3) The bamboo liquid particle compound (spraying 2 down/day) is obtained by dissolving the precipitate obtained in the step S2 of the application example in 50mL of distilled water;
4) 0.2% of bamboo liquid (spraying under 2/day), wherein the bamboo liquid content is calculated by mass percentage, namely the bamboo liquid with the same concentration is used in the step S1 of preparing the bamboo liquid particle compound;
5) Aqueous apatite (spray 2/day), wherein the apatite is carbonate, 440mM NaHCO 3 9mM NaH 2 PO 4 58mM CaCl 2 Adding water to prepare a solution with the total amount of 100 mL;
animal modeling: after all animals were housed in the house, the mice were dehaired to remove back hair and die-cast using DNCB induction. The 2% DNCB solution was administered at day 1 for initial sensitization at 150uL on the back and 10uL after ear administration, and the 0.5% DNCB solution was administered at days 5, 7, 9, 11, 13, 16, 18, 20, 22, 24 for challenge at 150uL on the back and 10uL after ear administration. On day 25, mice with a total score of 5 or more were evaluated for modeling success by skin damage scoring and scratching experiments.
The treatment process comprises the following steps: day0 given the corresponding drug treatment to each group of animals. The medicine 2 is sprayed at the skin lesion part according to the grouping until the death. From day of drug administration, day 2,4, 6, 8, 1 back skin condition was photographed every 2 days. After the observation is finished, the mice in each group are sacrificed to obtain the tissue of the damaged part, and after the fixing solution is fixed, pathological HE staining and immunohistochemical detection of FGF-2 expression are carried out.
The cure of the mice back dermatitis is shown in figure 2.
Statistical table of Day0 and Day4 skin damage scores as shown in fig. 3, skin damage scores were 4 parts: edema, hemorrhage, scaling, and exfoliation, each scored on a severity scale: 0-asymptomatic, 1-mild, 2-medium, 3-severe.
The fold line statistical graph of the skin inflammation skin damage scoring condition change of the mice is shown in fig. 4, the total inflammation score Day4 is shown in fig. 4, and compared with a model group, 0.2% bamboo liquid and apatite group, the 5% bamboo liquid and bamboo liquid particle compound treatment group has a remarkable anti-skin inflammation effect. Statistical values are expressed as mean ± standard error. Statistical evaluation using One-way ANOVA Tukey's multiple comparisons test, if P <0.05, it was judged significant
Sampling: on day 8, the lower skin tissue of the mice was removed under anesthesia and sectioned for pathological HE staining analysis, as shown in FIG. 5. In the model group, 0.2% bamboo liquid and carbonic apatite medicine treatment group are observed under an optical microscope, the horny layer of the skin tissue is hyperkeratosis and accompanied by hypokeratosis, and the dermis layer is infiltrated by a large amount of inflammatory cells; after 5% of bamboo liquid and bamboo liquid particle compound medicine treatment, inflammatory cell infiltration of dermis is obviously reduced, keratosis of stratum corneum is improved, and epidermis is thinned.
Immunohistochemical detection of FGF-2 expression As shown in FIG. 6, both 5% bamboo juice and bamboo juice particle complexes showed FGF-2 expression in dermal Langerhans cells/macrophage cells compared to the model group, 0.2% bamboo juice and apatite group.
Langerhans cells or macrophages in the epidermis can ingest and remove skin cells and wastes injured by heat, ultraviolet rays and physical injury, and promote proliferation of fibroblasts. Plays an important role in the immune monitoring of contact allergy, antiviral infection, rejection of allograft tissues and epidermal cancerous cells.
Basic fibroblast growth factor (FGF 2) plays a positive pathophysiological role in tissue remodeling, bone health and regeneration, such as repair of neuronal damage, healing of skin wounds. At present, the clinical experiments related to FGF2 recombinant protein treatment mainly surround the repair treatment of diseases such as oral cavity, periodontitis, tympanic membrane perforation, age-related macular degeneration and the like.
The anti-skin inflammatory effect of the bamboo liquid particle compound group is close to that of the bamboo liquid with higher mass concentration, which indicates that the bamboo liquid particle compound can increase the skin permeability of trace bamboo liquid, thereby amplifying the anti-inflammatory effect of the bamboo liquid.
Practical application
Fig. 7 is a case of using the bamboo liquid particle complex for a three month year old boy diagnosed with skin eczema. The bamboo liquid particle compound has obvious effect of resisting skin inflammation after being sprayed on the eczema part for 3 times a day and used for the fourth day.
Fig. 8 is a case of the bamboo liquid particle complex used by a one year old boy diagnosed with the mouth Zhou Shuizhen. The bamboo liquid particle compound has obvious effect of resisting skin inflammation after being sprayed on the eczema part 3 times a day and 7 days after being used.
The embodiments of the present application are all preferred embodiments of the present application, and the scope of the present application is not limited thereby, and the embodiments can be combined with each other for use, so: all equivalent changes in structure, shape and principle of the application should be covered in the scope of protection of the application.
Claims (7)
1. The bamboo liquid particle compound is applied to medicines or daily chemicals for treating dermatitis.
2. The use according to claim 1, wherein the bamboo liquor particle composite is a particle composite formed by bamboo liquor and apatite carbonate particles.
3. The use according to claim 2, wherein the bamboo liquid particle complex is applied in liquid or solid form in a medicament or daily chemical product for treating dermatitis.
4. The use according to claim 3, wherein the bamboo liquid particle complex is applied in the form of a solution or suspension in a medicament or daily chemical product for treating dermatitis.
5. The use according to claim 1, wherein the medicament or daily chemical product for treating dermatitis comprising the bamboo liquid particle complex is a liquid or a solid.
6. The use according to claim 5, wherein the medicament or daily chemical product for treating dermatitis comprising the bamboo liquid particle composite is any one of a lotion formulation, a spray formulation, a suspension formulation, a paste formulation, and a foam formulation.
7. The use according to claim 1, wherein the bamboo liquor particle complex promotes secretion of dermal langerhans cells and/or macrophages FGF-2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310985360.0A CN116870104A (en) | 2023-08-07 | 2023-08-07 | Application of bamboo liquid particle compound in medicines or daily chemicals for treating dermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310985360.0A CN116870104A (en) | 2023-08-07 | 2023-08-07 | Application of bamboo liquid particle compound in medicines or daily chemicals for treating dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116870104A true CN116870104A (en) | 2023-10-13 |
Family
ID=88266353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310985360.0A Pending CN116870104A (en) | 2023-08-07 | 2023-08-07 | Application of bamboo liquid particle compound in medicines or daily chemicals for treating dermatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116870104A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006509838A (en) * | 2002-11-12 | 2006-03-23 | 財団法人理工学振興会 | Cell introduction agent, cell introduction method, method for producing cell introduction agent, composition for producing cell introduction agent, and kit for producing cell introduction agent |
| CN1809391A (en) * | 2003-06-24 | 2006-07-26 | 国立大学法人九州大学 | Medical bone prosthetic material and process for producing the same. |
| CN109602623A (en) * | 2019-01-25 | 2019-04-12 | 云南群优生物科技有限公司 | A kind of bamboo liquid skin care item and preparation method thereof |
| CN116761631A (en) * | 2021-01-19 | 2023-09-15 | 山本浩文 | Composition for drug delivery, method for producing same, and use thereof |
-
2023
- 2023-08-07 CN CN202310985360.0A patent/CN116870104A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006509838A (en) * | 2002-11-12 | 2006-03-23 | 財団法人理工学振興会 | Cell introduction agent, cell introduction method, method for producing cell introduction agent, composition for producing cell introduction agent, and kit for producing cell introduction agent |
| CN1809391A (en) * | 2003-06-24 | 2006-07-26 | 国立大学法人九州大学 | Medical bone prosthetic material and process for producing the same. |
| CN109602623A (en) * | 2019-01-25 | 2019-04-12 | 云南群优生物科技有限公司 | A kind of bamboo liquid skin care item and preparation method thereof |
| CN116761631A (en) * | 2021-01-19 | 2023-09-15 | 山本浩文 | Composition for drug delivery, method for producing same, and use thereof |
Non-Patent Citations (1)
| Title |
|---|
| 何炳林, 马建标: "生物医用材料基础研究进展", 中国科学基金, no. 03, 23 June 1996 (1996-06-23), pages 165 - 172 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111956860B (en) | Liquid trehalose dressing for repairing skin barrier wound surface and preparation method thereof | |
| US20120328721A1 (en) | Aloe vera sprout concentrate or extract having superior skin cell growth promotion, antioxidant, and anti-allergy effects | |
| CN109125107B (en) | Polypeptide composition for effectively improving and repairing facial hormone-dependent dermatitis | |
| CN1947739B (en) | Traditional Chinese medicine composition for treating dermal titillation and chronic eczema and its preparation method | |
| KR102526210B1 (en) | Composition for improving skin regeneration and wound-healing comprising fermented Mastic Gum extract and method for manufacturing the same | |
| KR100990195B1 (en) | Allergic or atopic dermatitis-alleviating natural cosmetic composition | |
| CN108704021A (en) | The composition and preparation method impaired for skin allergy and skin barrier | |
| KR20100079586A (en) | Composition for anti atopy-dermatitis containing cirsium japonicum var. ussuriense extract | |
| CN116870104A (en) | Application of bamboo liquid particle compound in medicines or daily chemicals for treating dermatitis | |
| KR100887294B1 (en) | Cosmetic compositions containing hollyhock extracts | |
| CN113181240B (en) | Application of broussonetia papyrifera root bark in preparation of medicine for treating atopic dermatitis | |
| KR20030055154A (en) | A composition for treating a dermatitis and a method of preparing the same | |
| CN102772644B (en) | Traditional Chinese medicine composition and preparation with detumescence repairing function and preparation method thereof | |
| KR20100008541A (en) | Composition for promoting the differentiation of human mesenchymal stem cell to adipocytic cells containing the extracts of trichosanthis semen or cannabis semen | |
| CN109394801A (en) | The composition of the decomposition of the generation and promotion glycosylation end products for inhibiting glycosylation end products containing chestnut Herba Visci extract | |
| CN111202821B (en) | Traditional Chinese medicine extract with allergy-relieving and anti-inflammatory effects as well as preparation method and application thereof | |
| KR100552307B1 (en) | The cosmetic materials of adding a composite extracted from chinese medicine mterias having effect of antiageing | |
| KR20120009183A (en) | Composition for promoting the differentiation of human mesenchymal stem cell | |
| CN100457167C (en) | Externally used traditional Chinese medicine preparation for treating nasal mucosa erosion and nosebleed and its preparation method | |
| KR20160122052A (en) | Composition for treating wound containing stellera chamaejasme extract or fraction thereof and method for treating wound in a subject | |
| EP0342416A2 (en) | Medicine | |
| CN116870103A (en) | Application of bamboo liquid particle compound in medicines or daily chemicals for promoting skin wound healing | |
| CN110075193A (en) | Compound Lantana camara plant extracts and its preparation method and application | |
| KR20140114921A (en) | Aloe composition for moisturizing the skin | |
| CN114886794B (en) | Composition with anti-inflammatory and antioxidant effects and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |